Publications by authors named "C Haag"
Managers sometimes have a bad reputation as they are often perceived as more manipulative than other employees. This study focuses on the Dark Triad (DT)-comprising psychopathy, Machiavellianism, and narcissism-and its connection with managers' "Ability" Emotional Intelligence (AEI). The link between DT (measured through the Dirty Dozen) and managers' AEI (measured through QEPro, an AEI performance test) was examined through a Latent Profile Analysis (LPA).
View Article and Find Full Text PDFIntroduction: Understanding the prevalence of multiple sclerosis (MS) provides information for healthcare planning and helps identify trends and patterns of disease occurrence. For Switzerland, the number of persons with MS (pwMS) was last estimated at approximately 15,000 in 2016. The study's objectives were to update estimates of MS prevalence and characterise the change in MS prevalence in Switzerland between 2016 and 2021, the last year with complete administrative data.
View Article and Find Full Text PDFArtificial intelligence (AI) offers a wealth of opportunities for medicine, if we also bear in mind the risks associated with this technology. In recent years the potential future integration of AI with medicine has been the subject of much debate, although practical clinical experience of relevant cases is still largely absent. This case study examines a particular patient's experience with different forms of care.
View Article and Find Full Text PDFArticle Synopsis
- The article introduces MS Pattern Explorer, a tool designed to help analyze data from fitness wearables used by multiple sclerosis (MS) patients, aiming to improve understanding of symptoms and data exploration in clinical settings.
- Using a user-centered design, the tool addresses clinicians' needs for exploring and contextualizing activity and sleep patterns, employing interactive visuals to display meaningful data.
- Evaluation results show that MS Pattern Explorer effectively aids various participants in generating insights from complex data, indicating its potential use in clinical research for MS and possibly other chronic conditions.
Background: Janus kinase inhibitors (JAKi) have the potential to alter the landscape of atopic dermatitis (AD) management dramatically, owing to promising efficacy results from phase III trials and their rapid onset of action. However, JAKi are not without risk, and their use is not appropriate for all patients with AD, making this a medication class that dermatologists should understand and consider when treating patients with moderate-to-severe AD.
Objectives: To provide a consensus expert opinion statement from the International Eczema Council (IEC) that provides a pragmatic approach to prescribing JAKi, including choosing appropriate patients and dosing, clinical and laboratory monitoring and advice about long-term use.